

AD \_\_\_\_\_

Award Number: W81XWH-04-1-0859

TITLE: Molecular Characterization of Prostate Cancer Cell Oncolysis by Herpes Simplex Virus ICP0 Mutants

PRINCIPAL INVESTIGATOR: Karen Mossman, Ph.D.

CONTRACTING ORGANIZATION: McMaster University  
Hamilton, Ontario, Canada, L8N 3Z5

REPORT DATE: October 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**20060503167**

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

<b>1. REPORT DATE</b> 01-10-2005		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 15 Sep 2004 – 14 Sep 2005	
<b>4. TITLE AND SUBTITLE</b>  Molecular Characterization of Prostate Cancer Cell Oncolysis by Herpes Simplex Virus ICP0 Mutants				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-04-1-0859	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Karen Mossman, Ph.D.				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  McMaster University Hamilton, Ontario, Canada, L8N 3Z5				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  This report outlines the progress made on our Exploration: Hypothesis Development Award within the past 12 months. Briefly, the goals of the proposal were to characterize the oncolytic capacity of Herpes simplex virus type 1 ICP0 mutants in prostate cancer cells given the relationship between ICP0 and two tumor suppressors, RNase L and PML, implicated in prostate cancer progression. Here, we report that ICP0 prevents an RNase L-independent rRNA degradation event in infected cells (appended manuscript). We also provide preliminary evidence that suggests that the ability of ICP0-null HSV-1 mutants to selectively kill prostate cancer cells correlates with a reduction in PML levels. Furthermore, we briefly discuss experiments to be completed within the remaining six months of this award.					
<b>15. SUBJECT TERMS</b> prostate, oncolytic virus, herpes simplex virus, RNase L, PML					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  UU	<b>18. NUMBER OF PAGES</b>  45	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b> U	<b>b. ABSTRACT</b> U	<b>c. THIS PAGE</b> U			<b>19b. TELEPHONE NUMBER</b> (include area code)

## Table of Contents

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Table of Contents.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>5</b>
<b>Supporting Data.....</b>	<b>6</b>
<b>Key Research Accomplishments.....</b>	<b>9</b>
<b>Reportable Outcomes.....</b>	<b>10</b>
<b>Conclusions.....</b>	<b>11</b>
<b>References.....</b>	<b>12</b>
<b>Appendices.....</b>	<b>13</b>

## Introduction

Current cancer therapies often have limited efficacy and high toxicity and thus novel approaches to treatment are sought. Recent work has focused on viruses as potential anti-cancer agents [1, 2]. The study of viruses has greatly increased our knowledge of many basic principles of biology, including cell growth control and tumorigenesis, along with our understanding of how viruses exploit their host to enable their replication. With this greater comprehension comes the ability to manipulate viruses to target and lyse cancerous cells. Some viruses are naturally oncotropic while others are being engineered to selectively replicate in tumor cells. Oncolytic viruses obtain their specificity by exploiting cell surface or intracellular defects in gene expression during tumor evolution. Recent studies indicate that many such defects lie in interferon (IFN) pathways [3-6], given the potent antiproliferative activity of IFN and its downstream mediators [7, 8]. At least two tumor suppressors, RNase L and PML, are regulated by IFN and have been implicated in prostate cancer. Linkage analyses demonstrated that the hereditary prostate cancer locus, HPC1, mapped specifically to the *RNASEL* gene and segregated within families with the most severe cases of prostate cancer [9]. RNase L degrades both viral and cellular rRNA, leading to protein synthesis inhibition and apoptosis [10]. PML is a ubiquitously expressed nuclear phosphoprotein shown to block the initiation, promotion and progression of a variety of tumors [11]. PML concentrates in sub-nuclear structures called ND10 and suppresses cell growth by inducing cell cycle arrest or apoptosis. Although PML protein expression is reduced or abolished in many human cancers, tumor tissue microarrays showed the highest percentage of reduction in prostate adenocarcinomas [12]. Furthermore, loss of PML was associated with tumor progression in prostate, breast and CNS cancers. Given that PML and RNase L are well-characterized ISGs, it has been suggested that defects in pathways involving apoptosis and innate immunity may be critical for prostate cancer initiation [13]. The human herpesvirus HSV-1 was the first virus to be engineered for oncolytic virus therapy. We recently published that mutants of HSV-1 lacking the immediate early protein ICP0 demonstrate enhanced oncolytic capacity in a mouse model of breast adenocarcinoma [14]. Pertinent to this project, ICP0 degrades PML [15, 16] and blocks the degradation of rRNA (Appendix 1), leading to the hypothesis that disruption of anti-viral and anti-proliferative pathways in prostate cancer cells render them sensitive to ICP0-null HSV mutants.

## Body

In our Statement of Work, we proposed four general aims to characterize prostate cancer cell oncolysis by Herpes simplex virus type 1 (HSV-1) ICP0 mutants based on previous work implicating the IFN regulated tumor suppressors RNase L and PML in prostate cancer progression. For each aim listed below, a summary of our research accomplishments will be given. A graduate student, Paul Sobol, was recruited in September 2004 to work on this project.

1. Determine the role of ICP0 in preventing 28S & 18S rRNA degradation and its relationship to RNase L.

We had previously observed that infection of cells with HSV-1 mutants bearing lesions in ICP0 resulted in rRNA degradation at late times of infection. Since RNase L mediates antiviral immunity by degrading rRNA and we have shown that ICP0 blocks IFN activity [17, 18], we investigated the relationship between RNase L and ICP0. As outlined in the attached manuscript (Appendix), we found that ICP0 blocks rRNA degradation in an RNase L-independent fashion. This manuscript has been accepted (pending modifications) to Journal of Virology.

2. Determine the oncolytic properties of ICP0 mutant viruses in normal and cancerous prostate cells.


We have screened established normal and metastatic prostate cell lines, including RWPE-1 (normal human prostate epithelial), PC3 (bone metastasis derived), DU145 (brain metastasis derived) and LNCaP (lymph node metastasis derived) for their susceptibility to oncolysis with a series of ICP0 mutant viruses (KM100, KM110 and KM120). As outlined in Figure 1, LNCaP are the most permissive to infection by these viruses. Of interest, only LNCaP is refractory to type I IFN [19], due to the lack of a critical component of the IFN signaling pathway [20], and is the most differentiated of the three cancer lines.

3. Correlate tumor cell permissiveness with RNase L and PML levels and activities.

Given that ICP0 appears to block rRNA degradation mediated by a ribonuclease distinct from RNase L, we have focused our studies on the tumor suppressor PML. We have preliminary data suggesting that decreased levels of PML correlate with increased susceptibility to oncolysis with HSV-1 mutants lacking ICP0 (Figure 2). In agreement with Figure 2, LNCaP demonstrate the greatest reduction in PML levels of the three prostate cancer cell lines. We are confirming these studies by looking at total cellular levels of PML by western blot analysis.


4. Develop a murine model of prostate cancer to test the oncolytic ability of ICP0 mutant viruses.

We have completed an *in vivo* assessment of the oncolytic capacity of the HSV-1 ICP0 mutant KM100 in a mouse model of breast adenocarcinoma [14]. These findings will serve as a platform for *in vivo* studies of prostate cancer oncolysis. Given that in the breast cancer model, infection with KM100 elicited a strong anti-tumor immune response and rendered mice resistant to subsequent tumor challenge, we chose to investigate an immunocompetent mouse model of prostate cancer (TRAMP model). We have ordered TRAMP-C1, -C2 and -C3 cells from the ATCC and will begin these studies shortly.




**Figure 1.** (A) Average viral titres per one million cells, adjusted to log scale. Cell lines tested were normal/tumor pairs for bone and prostate tissues.

**B**



**Figure 1. (B)** Cytopathic effect (CPE) of ICP0-null mutant HSV on normal/tumor bone and prostate cell lines. Mock treatment (no virus) represents no CPE, whereas KOS infection represents a positive control for CPE.



**Figure 2.** Immunofluorescent microscopy examining the expression and localization of the nuclear body protein PML. Monoclonal anti-PML antibody (red) detection of punctate PML in normal/tumor bone and prostate cell lines. Dapi (blue) identifies the nuclei.



### **Key Research Accomplishments**

- Submission of a manuscript entitled "ICP0 prevents RNase L-independent rRNA cleavage in HSV-1-infected Cells" to Journal of Virology (accepted pending modification).

### **Reportable Outcomes**

- Submission of a manuscript entitled "ICP0 prevents RNase L-independent rRNA cleavage in HSV-1-infected Cells" to Journal of Virology (accepted pending modification).
- Submission of grant application entitled "Herpes virus based oncolytic viruses for cancer therapy" to Canadian Institutes of Health Research, National Cancer Institute of Canada and The Ontario Cancer Research Network.
- Invitation to speak at the 2006 Gordon Research Conference on the Science of Viral Vectors, Gene Expression and Applications on our oncolytic virus program.

## **Conclusions**

In conclusion, we have made progress on each of the four aims outlined in our original statement of work. In particular, the work outlined in the first aim was recently submitted for publication and accepted pending modification of the manuscript. In combination with our studies on breast cancer, the work supported by the US Army Medical Research and Materiel Command has yielded sufficient information to warrant submission of a full operating grant from the top two Canadian research institutes, CIHR and NCIC. We are grateful for the funds provided through the Exploration & Hypothesis Development program.

## References

1. Norman, K.L., F. Farassati, and P.W.K. Lee, *Oncolytic viruses and cancer therapy*. Cytokine and Growth Factor Reviews, 2001. **12**: p. 271-282.
2. Ring, C.J., *Cytolytic viruses as potential anti-cancer agents*. J Gen Virol, 2002. **83**(Pt 3): p. 491-502.
3. Stojdl, D.F., et al., *Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus*. Nature Medicine, 2000. **6**(7): p. 821-5.
4. Sun, W.H., et al., *Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression*. Blood, 1998. **91**(2): p. 570-6.
5. Wong, L.H., et al., *Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma*. Journal of Biological Chemistry, 1997. **272**(45): p. 28779-85.
6. Li, Y., K.K. Srivastava, and L.C. Platanias, *Mechanisms of type I interferon signaling in normal and malignant cells*. Arch Immunol Ther Exp (Warsz), 2004. **52**(3): p. 156-63.
7. Stark, G.R., et al., *How cells respond to interferons*. Annual Review of Biochemistry, 1998. **67**: p. 227-64.
8. Platanias, L.C., *Mechanisms of type-I- and type-II-interferon-mediated signalling*. Nat Rev Immunol, 2005. **5**(5): p. 375-86.
9. Silverman, R.H., *Implications for RNase L in prostate cancer biology*. Biochemistry, 2003. **42**(7): p. 1805-1812.
10. Player, M.R. and P.F. Torrence, *The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation*. Pharmacol Ther, 1998. **78**(2): p. 55-113.
11. Salomoni, P. and P.P. Pandolfi, *The Role of PML in Tumor Suppression*. Cell, 2002. **108**(2): p. 165-70.
12. Gurrieri, C., et al., *Loss of the tumor suppressor PML in human cancers of multiple histologic origins*. J Natl Cancer Inst, 2004. **96**(4): p. 269-79.
13. Montironi, R., M. Scarpelli, and A. Lopez Beltran, *Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors*. Virchows Arch, 2004. **444**(6): p. 503-8.
14. Hummel, J.L., E. Sarroneeva, and K.L. Mossman, *The role of ICP0 null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma*. Molecular Therapy, 2005. **Epub ahead of print**.
15. Chelbi-Alix, M.K. and H. deThe, *Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins*. Oncogene, 1999. **18**: p. 935-941.
16. Everett, R.D., *ICP0, a regulator of herpes simplex virus during lytic and latent infection*. Bioessays, 2000. **22**(8): p. 761-70.
17. Mossman, K.L., H.A. Saffran, and J.R. Smiley, *Herpes simplex virus ICP0 mutants are hypersensitive to interferon*. Journal of Virology, 2000. **74**(4): p. 2052-6.
18. Mossman, K.L. and J.R. Smiley, *Herpes Simplex Virus ICP0 and ICP34.5 Counteract Distinct Interferon-Induced Barriers to Virus Replication*. J. Virol., 2002. **76**(4): p. 1995-1998.
19. Goldstein, D., et al., *Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines*. J Urol, 1991. **146**(4): p. 1173-7.
20. Dunn, G.P., et al., *IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression*. Cancer Res, 2005. **65**(8): p. 3447-53.

1  
2  
3  
4  
5  
6  
7 **ICP0 prevents RNase L-independent rRNA cleavage in HSV-1-infected Cells**  
8

9 Running Title: HSV-1 ICP0 blocks rRNA degradation  
10

11  
12  
13  
14 Paul T. Sobol<sup>1</sup>, and Karen L. Mossman<sup>1,2\*</sup>  
15

16 Departments of Biochemistry & Biomedical Sciences<sup>1</sup> and Pathology & Molecular Medicine<sup>2</sup>,  
17 Centre for Gene Therapeutics, McMaster University, Hamilton L8N 3Z5, Canada  
18  
19

20 Abstract Word Count: 142

21 Text Word Count: 3836  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 **\*Corresponding Author:**

33 Mailing address:

34 Department of Pathology & Molecular Medicine

35 MDCL 5026

36 1200 Main Street West

37 Hamilton, Ontario

38 Canada

39 L8N 3Z5

40 Email: [mossk@mcmaster.ca](mailto:mossk@mcmaster.ca)

41 Phone: (905) 525-9140

42 Fax: (905) 522-6750

**ABSTRACT**

The classical interferon (IFN)-dependent antiviral response to viral infection involves the regulation of IFN-stimulated genes (ISGs), one being the cellular endoribonuclease RNase L that arrests protein synthesis and induces apoptosis by nonspecifically cleaving ribosomal RNA (rRNA). Recently, the herpes simplex virus type-1 (HSV-1) protein ICP0 has been shown to block the induction of ISGs by subverting the IFN pathway upstream of the oligoadenylate synthetase (OAS)/RNase L pathway. We report that ICP0 also prevents rRNA degradation at late stages of HSV-1 infection, independent of its E3 ubiquitin ligase activity, and that the resultant rRNA degradation is independent of the classical RNase L antiviral pathway. Moreover, the degradation is independent of the viral ribonuclease vhs, and is independent of IFN response factor-3 (IRF-3). These studies indicate the existence of another, previously unidentified ribonuclease, that is part of the host antiviral response to viral infection.

## INTRODUCTION

Viral infection of mammalian cells induces a robust antiviral response intended to restrict viral replication and propagation. A predominant characteristic of this innate immune response is the expression and secretion of interferons (IFNs), a family of immunomodulatory cytokines with antiviral and antiproliferative activities (43). Once secreted from infected cells, the type I IFNs (IFN  $\alpha,\beta$ ) bind to their cognate class II cytokine receptors in both paracrine and autocrine fashions, and induce the phosphorylation of Jak/Stat molecules, leading to the nuclear translocation of activated Stat1-Stat2-IRF9 heterotrimers. These complexes bind to the IFN-stimulated response element (ISRE) in promoters of IFN-stimulated genes (ISGs), resulting in the robust induction of these antiviral effector molecules. Among the ISGs most intently studied are the dsRNA-dependent protein kinase R (PKR), which induces protein synthesis arrest (52), and the ubiquitous 2'-5' oligoadenylate synthetase (OAS) family of proteins which function to promote RNA degradation (44). Once upregulated, PKR and OAS become activated by binding to dsRNA, a by-product of viral replication.

OAS catalyzes the synthesis of variable short 2'-5' linked oligoadenylates (2'-5'A) from ATP, which in turn activate the latent endoribonuclease RNase L to cleave cellular and viral RNA (36). Infection with several viruses, including vaccinia virus and encephalomyocarditis virus, leads to RNase L-dependent ribosomal RNA (rRNA) degradation (44). Ultimately, rRNA cleavage results in protein synthesis inhibition and apoptosis, and constitutes a significant cellular antiviral event to prevent viral propagation (7). Indeed, several viruses have evolved specific mechanisms to counteract the 2'-5'A pathway, including human immunodeficiency virus-1, vaccinia virus and the  $\alpha$ -herpesvirus herpes simplex virus type 1 (HSV-1) (8, 27, 53). HSV-1 infection of conjunctival cells induces the synthesis of 2'-5'A derivatives, which

antagonize RNase L activation by competing with genuine 2'-5' A for binding to ankyrin repeats 7 and 8 on RNase L. In addition, HSV-1, like many other viruses, has been shown to inhibit IFN signaling pathways upstream of RNase L activation at multiple points (25, 31, 54, 55).

Taken together, it appears that preventing cellular rRNA degradation is of great importance to viral propagation, and viral interference in the IFN-regulated OAS/RNase L pathway is paramount for viral replication and spread. Despite these observations, there is conflicting evidence for the specific contribution of RNase L towards an antiviral state in HSV-1 infected cells. Studies with wild type (wt) and RNase L-knockout cells illustrated that HSV-1 infection does not significantly induce RNase L activity *in vitro* (47) and that the absence of RNase L does not significantly affect viral growth and virulence in an *in vivo* ocular model of HSV-1 infection (24). This observation is in contrast to another study that concluded HSV-1 infection of RNase L-knockout mice induces a significantly higher mortality rate and heightened susceptibility to herpetic disease and stromal keratitis compared to HSV-1 infection of wt infected mice (57). These data suggest that either RNase L does not significantly contribute to host defense against HSV-1 infection, or RNase L, as a component of the IFN signaling antiviral pathway, is inhibited during the course of HSV-1 infection by a viral factor.

Expressed early in infection, the HSV-1 immediate early (IE) protein infected cell protein 0 (ICP0) is a multifunctional transcriptional activator of viral and cellular genes that synergistically functions with another IE protein, ICP4, for several of its transcriptional functions (14). In the absence of ICP0, initiation of lytic replication is diminished, and latent genomes reactivate with decreased kinetics. In addition, ICP0 is responsible for surmounting a variety of cellular antiviral responses (14, 30-32). Upon translocating to the nucleus early in infection, ICP0 promotes the proteasome-dependent degradation of an array of cellular antiviral ISGs,



1 including the nuclear body-associated proteins promyelocytic leukemia protein (PML) and  
2 Sp100 (9, 15, 34). To date, ICP0's biological effects have been found to require the N-terminal  
3 RING finger domain, which mediates E3 ubiquitin ligase activity (3). The resultant disruption of  
4 ND10 nuclear bodies, in addition to other IFN-induced pathways, diminishes cellular antiviral  
5 capacity. Recently, ICP0 has been shown to block ISG expression by inhibiting the key  
6 transcriptional activators IFN regulatory factor (IRF) 3 and IRF7 (12, 25, 29). Moreover, ICP0  
7 functions to counteract an IFN-induced barrier to virus replication (32, 33).

8         Since ICP0 is involved in subverting IFN signaling during the innate immune response to  
9 HSV-1 infection and RNase L-mediated rRNA degradation is a component of the cellular  
10 antiviral response, we set out to determine if ICP0 prevents cellular rRNA degradation during  
11 HSV-1 infection. We report that in the absence of ICP0 expression, HSV infection results in  
12 RNase L- and IRF3-independent rRNA degradation in a variety of cell types at late times post  
13 infection. The resultant rRNA degradation is independent of both the virion host shutoff (vhs)  
14 ribonuclease, and the E3 ubiquitin ligase activity of ICP0. These studies provide further  
15 evidence for the existence of another, previously unidentified cellular endoribonuclease that is  
16 part of a host antiviral response to viral infection.

## MATERIALS AND METHODS

**Cells and viruses.** Human embryonic lung (HEL) fibroblast, HepG2 hepatoma, U2OS osteosarcoma and Vero monkey kidney epithelial cells were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% (Vero) or 10% (HEL, HepG2 and U2OS) fetal bovine serum (FBS) and 2mM L-glutamine. RNase L<sup>-/-</sup> and RNase L<sup>+/+</sup> murine embryo fibroblasts (MEFs; genetic background C57BL/6) (58) and IRF3<sup>-/-</sup> and IRF3<sup>+/+</sup> MEFs (genetic background C57BL/6) (41) were maintained in  $\alpha$  MEM supplemented with 10% FBS and 2mM L-glutamine. A listing of all HSV-1 viruses used in this study is provided in Table 1. AdMLP0 is a type 5 adenovirus expressing ICP0 under the major late promoter while AdE1E3 is a control adenovirus containing deletions of the E1 and E3 transcriptional units (59). Wild-type and IE mutant HSV-1 infections were completed at a multiplicity of infection (MOI) of 1 and 5 PFU per cell, respectively, in serum free DMEM for 1 hour. Adenovirus infections were completed at a MOI of 100 PFU/cell in phosphate buffered saline supplemented with 0.01% MgCl<sub>2</sub> and 0.01% CaCl<sub>2</sub> for 45 minutes. UV inactivation of viruses was performed with a UV Stratalinker 2400 (Stratagene) for the length of time required to drop infectious titres by greater than 5 orders of magnitude. Unless otherwise indicated, total cellular RNA was extracted 3 days after wt or mutant HSV infection, and 24 hours after adenovirus infection.

**PolyIC Transfections and Treatments.** Polyinosinic-polycytidylic acid (polyIC, Amersham-Pharmacia) was reconstituted in PBS at 5 mg/mL, denatured at 55°C for 15 min, and left to anneal at room temperature prior to transfection. Unless otherwise indicated, all cell lines were transfected with 1  $\mu$ g polyIC per mL or 500 ng 2'-5'A (R. Silverman) using the Lipofectamine transfection reagent (Invitrogen) according to the manufacturers protocol.

1 **RNA Extraction and Analysis.** RNA was harvested using Trizol (Life Technologies) according  
2 to the manufacturer's recommendations. 5 µg of RNA was diluted into a 3-N-morpholino  
3 propansulfonic acid (MOPS) solution containing 20% formaldehyde and 50% formamide.  
4 Samples were subjected to agarose-gel electrophoresis (1% agarose, 20% formaldehyde) in  
5 MOPS running buffer in the presence of ethidium bromide (EtBr) for 1.5 hours at a potential  
6 difference of 100 V. RNA gels were scanned using the Typhoon Imager (Amersham  
7 Biosciences) using ImageQuant (Amersham Biosciences) software.

8

## RESULTS

**ICP0 Prevents HSV-1-induced rRNA Degradation.** Given the role of ICP0 in mediating host antiviral responses, we sought to determine if ICP0 prevented rRNA degradation in HSV-1 infected cells by monitoring rRNA degradation following wt and ICP0-null HSV infection. Although ICP0 mutants are grown under complementing conditions, their titres are reproducibly 5-fold lower than that of wt virus (data not shown), due to an increase in the particle to pfu ratio (48). Thus in this and subsequent experiments, we utilized MOIs of 1 and 5 for wt and ICP0-null HSV infections, respectively. Under these conditions, the overall level and kinetics of viral protein expression in human embryonic lung (HEL) fibroblasts were similar (data not shown). As shown in Figure 1A, HEL fibroblasts infected with various ICP0-null HSV-1 mutants (described in Table 1), but not wt HSV-1, demonstrated cellular 28S and 18S rRNA degradation after 3 days of infection. To determine if the rRNA degradation pattern was consistent with an RNase L-mediated event, we transfected HEL fibroblasts with polyinosinic-polycytidylic acid (polyIC), a synthetic dsRNA polyribonucleotide derivative. rRNA degradation characteristic of RNase L activation was observed upon transfection of polyIC with Lipofectamine (LF), but not following treatment with either component on its own. Identical patterns were observed when 2'-5'A was used in place of polyIC (data not shown). The degradation patterns observed following transfection of polyIC or infection with ICP0-null HSV-1 were dissimilar, suggesting that RNase L may not mediate rRNA degradation following HSV-1 infection in the absence of ICP0 expression. One possible explanation for the disparate rRNA degradation profiles is a difference in degradation kinetics. To address this possibility, HEL fibroblasts were either transfected with polyIC or infected with ICP0-null HSV-1. As shown in Figure 1B, polyIC-induced rRNA degradation appears within the first hour of transfection, with complete 28S

1 rRNA degradation occurring within three hours, and involves the formation of a series of  
2 complex degradation products. In contrast, rRNA degradation following infection with ICP0-  
3 null HSV-1 is a late stage event, with observable degradation two days post-infection, and  
4 involves the formation of only two major rRNA degradation products.

5 In order to determine if the rRNA degradation following HSV-1 infection occurs in the  
6 absence of ICP0 with viral strains other than KOS, we infected HEL fibroblasts with wt strain 17  
7 and its ICP0-null derivative dl1403. As shown in Figure 1C, dl1403 induced an identical  
8 degradation pattern to that of 7134, which was absent in 17syn<sup>+</sup> infected cells. Infection with the  
9 strain 17-derived ICP0 RING finger domain mutant FXE, which has abolished E3 ubiquitin  
10 ligase activity, did not elicit rRNA degradation.

11 Previous studies of HSV-1 replication have shown that ICP0 functions synergistically  
12 with other IE proteins, such as ICP4, in mediating some of its biological functions (14). To  
13 determine if ICP0 is the sole IE protein required for the prevention of rRNA degradation, HEL  
14 fibroblasts were infected with a panel of single IE mutant viruses (refer to Table 1). Aside from  
15 7134, no other IE mutant virus infection induced rRNA degradation (Figure 1D), illustrating that  
16 ICP0 is the only IE protein required for the prevention of rRNA degradation in HSV-1 infected  
17 HEL fibroblasts.

18  
19 **Cell type specificity of ICP0-null HSV-1-induced rRNA degradation.** Since the expression  
20 of RNase L is cell type specific (21, 35), we set out to determine if the rRNA degradation  
21 observed in ICP0-null HSV-1 infected HEL fibroblasts can occur in other cell types. Infection of  
22 human osteosarcoma (U2OS; Figure 2A) and hepatoma (HepG2; Figure 2B) cells with ICP0-null  
23 HSV-1 mutants induced an rRNA degradation pattern similar to that in HEL fibroblasts, while  
24 KOS-infected cells displayed intact rRNA. Infection of green monkey kidney epithelial (Vero)

1 and human alveolar epithelial (A549) cells with ICP0-null HSV-1 induced rRNA degradation  
2 comparable to that of U2OS cells (data not shown). Notably, the extent of rRNA degradation  
3 was reproducibly less in these cell lines as compared to HEL fibroblasts (Figure 1A). As with  
4 HEL fibroblasts, polyIC transfection induced rRNA degradation in A549, Vero and U2OS cells,  
5 indicating the presence of functional RNase L. In contrast, polyIC transfection of HepG2 cells  
6 did not induce rRNA degradation (Figure 2B), which is consistent with the lack of functional  
7 RNase L in this cell line (49).

8  
9 **rRNA degradation in ICP0-null HSV-1 infected cells is independent of RNase L.** Given the  
10 difference in rRNA degradation patterns between transfected and infected cells (Figure 1A and  
11 B) and the ability to induce rRNA degradation following infection in RNase L-deficient HepG2  
12 cells (Figure 2B), we set to conclusively determine the role of RNase L in mediating rRNA  
13 degradation following ICP0-null HSV-1 infection. We infected wt murine embryo fibroblasts  
14 (MEFs; Figure 3A) and RNase L<sup>-/-</sup> MEFs (Figure 3B) with KOS, 7134, dIX3.1, or n212. Both  
15 wt and RNase L<sup>-/-</sup> MEFs infected with ICP0-null HSV-1 displayed an rRNA degradation pattern  
16 similar to that in HEL fibroblasts. Consistent with the lack of RNase L, polyIC-induced rRNA  
17 degradation was observed in wt but not RNase L<sup>-/-</sup> MEFs. Taken together, the rRNA degradation  
18 observed following HSV-1 infection in the absence of ICP0 expression occurs independent of  
19 RNase L.

20  
21 **rRNA degradation in ICP0-null HSV-1 infected cells is independent of the viral**  
22 **ribonuclease vhs.** Since the rRNA degradation observed following ICP0-null HSV-1 infection  
23 occurs in the absence of RNase L, then either a viral or an alternative cellular ribonuclease is  
24 responsible for the observed degradation. Previously, the HSV-1 virion host shutoff protein

(vhs) was shown to induce a rapid arrest of macromolecular biosynthesis by associating with the cellular transcription factor eIF4H and inducing non-specific destabilization of cellular and viral mRNA (45). Due to its nuclease activity, we sought to determine if vhs contributes to the rRNA degradation observed following HSV-1 infection in the absence of ICP0 expression by infecting HEL fibroblasts with wt HSV-1, or mutants deficient in ICP0 and/or vhs. While ICP0-null HSV (7134 and 7134 $\Delta$ sma) infected cells displayed rRNA degradation, KOS and vhs-null HSV infected cells possessed intact rRNA (Figure 4), illustrating that the rRNA degradation observed following HSV-1 infection in the absence of ICP0 expression is independent of vhs.

**ICP0 overexpression does not prevent RNase L-mediated rRNA degradation.** We have shown that infection with HSV-1 leads to RNase L-independent rRNA degradation that is blocked upon expression of ICP0. However, it remains unclear if ICP0 is capable of also counteracting the IFN-mediated RNase L pathway. To determine if ICP0 expression is sufficient to block RNase L-mediated rRNA degradation, we infected Vero cells with an adenovirus encoding ICP0 under the transcriptional control of the major late promoter (AdMLP0), and subsequently challenged the infected cell cultures with polyIC transfection or ICP0-null HSV infection (7134). Immunofluorescence microscopy illustrated that approximately 80% of cells expressed ICP0 following AdMLP0 infection (data not shown). In addition, western blot analysis of AdMLP0- and KOS-infected cell lysates indicated that both viruses expressed similar amounts of ICP0 (data not shown). While ICP0 pre-expression prevented rRNA degradation in 7134-infected cells, thus restoring a wt phenotype, it did not prevent polyIC-induced, RNase L-mediated rRNA degradation (Figure 5), illustrating that ICP0 does not inhibit RNase L-mediated rRNA degradation. Infection with a control adenovirus (AdE1E3) did not complement the ICP0-null phenotype. Moreover, polyIC transfection following KOS infection induced rRNA

1 degradation, indicating that wt HSV does not prevent RNase L-mediated rRNA degradation  
2 (data not shown). Similar results were observed in AdMLP0-infected A549 cells (data not  
3 shown). To corroborate these observations, we utilized O-28 cells, a stable Vero-derived cell line  
4 that expresses ICP0 under the control of its endogenous promoter. Under these conditions,  
5 similar results to Figure 5 were observed (data not shown). Therefore, whether expressed by a  
6 recombinant adenovirus, wt HSV or within a stable cell line, ICP0 expression does not prevent  
7 RNase L-mediated rRNA degradation.

8  
9 **rRNA degradation in ICP0-null HSV-1 infected cells is independent of IRF3.** Given that  
10 rRNA degradation is a hallmark of apoptosis (19), and that ICP0 blocks IRF3 (25), a  
11 transcription factor implicated in apoptosis (20), we set out to determine the role of IRF-3 in  
12 RNase L-dependent and -independent rRNA degradation. Wt and IRF3<sup>-/-</sup> MEFs (Figure 6A and  
13 6B, respectively) were transfected with polyIC or infected with wt or ICP0-null HSV-1. Both wt  
14 and IRF3<sup>-/-</sup> MEFs infected with ICP0-null HSV-1 displayed rRNA degradation similar to that  
15 observed in HEL fibroblasts. Notably, polyIC-mediated rRNA degradation was not observed in  
16 IRF3<sup>-/-</sup> MEFs, suggesting that IRF3 is essential for RNase L-mediated rRNA degradation.

17 To confirm these results, we investigated rRNA profiles following transfection of polyIC  
18 or infection with ICP0-null HSV-1 in Jak1-deficient parental cells (U4C) or a derivative, P2.1,  
19 that expresses only low levels of IRF3 (23). While polyIC-induced, RNase L-mediated rRNA  
20 degradation was markedly reduced in P2.1 cells compared to U4C cells, HSV-1-mediated rRNA  
21 degradation was similar in both (data not shown). Taken together, these data indicate that while  
22 ICP0-null HSV-1-induced rRNA degradation is IRF3-independent, polyIC-induced, RNase L-  
23 mediated rRNA degradation requires IRF3.



## DISCUSSION

The innate antiviral response to viral replication involves the combined activities of ISGs in an effort to suppress viral replication and to induce apoptosis of infected cells to limit viral spread. Once activated by dsRNA, the endoribonuclease RNase L mediates both of these responses following infection with viruses such as vaccinia virus and encephalomyocarditis virus (7). Although HSV-1 has been shown to block RNase L-mediated RNA degradation by synthesizing decoy 2-5A derivatives that antagonize RNase L activity (8), the specific contribution of RNase L towards host antiviral capacity remains controversial. However, HSV-1 countermeasures to other IFN pathways are well documented (30).

Since the HSV-1 IE protein ICP0 has been shown to be instrumental in surmounting several of these IFN-dependent antiviral pathways, we investigated the possibility that ICP0 prevents cellular rRNA degradation following HSV-1 infection by blocking RNase L activity. We observed that in the absence of ICP0 expression, HSV-1 strains 17 and KOS induced rRNA degradation at late stages post-infection. Individual deletion of the remaining IE gene products failed to demonstrate hallmarks of rRNA degradation. While this observation suggests that ICP0 is necessary to block rRNA degradation, it does not discount the possibility that an additional viral protein(s) is also involved. It is well established by Blaho and colleagues that ICP27-null HSV infection results in many of the hallmarks associated with apoptosis through the destabilization of cellular Bcl-2 protein and a reduction in Bcl-2 RNA levels, including DNA fragmentation (1, 56). However, evidence exists which illustrates that rRNA degradation is a cell-type dependent occurrence that is independent of DNA fragmentation (39).

Intracellular antiviral pathways are predominantly mediated by immediate early response factors and are thus activated at early times of infection. Here, however, we detected rRNA

1 degradation at late times of infection. While we currently do not fully understand the biological  
2 implications of a delayed cellular immune response, a number of factors could impact on the  
3 delayed kinetics we observed. As mentioned above, it is likely that viral proteins other than ICP0  
4 assist in blocking this cellular antiviral response. Viruses routinely encode multiple proteins to  
5 disable cellular antiviral pathways (40, 42). Under conditions where only ICP0 activity is absent,  
6 rRNA degradation would remain partially inhibited with subsequent degradation products  
7 requiring sufficient accumulation to become visible. Furthermore, these experiments were  
8 performed *in vitro* using relatively high multiplicities, conditions that may not reflect *in vivo*  
9 infections. We believe that these events are relevant to HSV biology, however, since rRNA  
10 degradation in the absence of ICP0 was observed in all cell types tested, particularly in mouse  
11 embryo and HEL fibroblasts. As opposed to the continuous cell lines tested, these fibroblasts are  
12 non-immortalized and non-transformed. Given that IFN is both anti-viral and anti-proliferative  
13 in nature, it is likely that IFN-mediated immune responses are more intact in “primary” cells as  
14 opposed to immortalized or transformed cells. Furthermore, in a series of burst experiments, we  
15 noted a decrease in ICP0-null viral titres that correlated with an increase in rRNA degradation,  
16 whereas no significant drop in wt viral titres was observed during the course of the experiment  
17 (data not shown).

18       Of particular interest, the ICP0 RING finger mutant was capable of blocking rRNA  
19 degradation, illustrating that the E3 ubiquitin ligase activity of ICP0 does not contribute to  
20 preventing rRNA degradation. Although ICP0 contains multiple functional domains, including a  
21 nuclear localization signal (NLS), a herpesvirus associated ubiquitin specific protease (HAUSP)  
22 binding domain and an ND10 localization domain, the biological functions of ICP0 have to date  
23 been found to rely on its E3 ubiquitin ligase activity (14, 25). Therefore, this is the first ICP0-

regulated biological phenomenon that is independent of ICP0's E3 ubiquitin ligase activity. Studies are underway to determine the mechanism(s) whereby ICP0 blocks rRNA degradation following HSV-1 infection.

There are three mutually exclusive mechanisms that could account for the observed rRNA degradation following ICP0-null HSV-1 infection. In the first mechanism, RNase L mediates cellular rRNA degradation in response to HSV-1 infection, and ICP0 prevents this by either directly inhibiting RNase L or indirectly blocking an upstream activator of the OAS-RNase L pathway. We provide evidence, however, that RNase L is not mediating rRNA cleavage following HSV-1 infection. In addition to the RNase L-deficient hepatoma cell line (HepG2), both control MEFs and RNase L knockout MEFs infected with ICP0-null HSV-1 displayed rRNA degradation. Furthermore, RNase L-mediated rRNA degradation exhibits markedly different kinetics from that of ICP0-null HSV-1-induced rRNA degradation and produces a disparate rRNA degradation profile. In addition, ICP0 overexpression did not prevent RNase L specific rRNA cleavage, further illustrating that ICP0 does not block the OAS-RNase L pathway during HSV-1 infection. Recently, a polyIC-containing liposome complex (NS-9) was shown to induce rRNA degradation in an IRF3-dependent manner (51). In agreement with these data, we report that polyIC-induced, RNase L-mediated rRNA degradation is IRF3 dependent, and further conclude that ICP0-null HSV-1-induced rRNA degradation is IRF3-independent. Taken together, these data illustrate that ICP0 prevents an RNase L- and IRF3-independent rRNA degradation event that is induced following HSV-1 infection. These results also parallel those of other studies that determined RNase L activity does not contribute to the host antiviral response during HSV-1 infection (24, 47). Interestingly, RNase L activity does

not contribute to cellular antiviral responses during infection with VZV, a related  $\alpha$ -herpesvirus (11).

In a second putative mechanism, the rRNA degradation observed following ICP0-null HSV-1 infection is mediated by the viral ribonuclease vhs. However, in the absence of ICP0 and vhs, rRNA degradation was still prominent in HEL fibroblasts, discrediting vhs as the causative ribonuclease. This conclusion is in agreement with previous research illustrating that rRNA is resistant to vhs-mediated degradation (16, 22).

In the last mechanism, HSV-1 induces the activity of a cellular ribonuclease other than RNase L, and ICP0 blocks the resultant rRNA degradation. Indeed, certain cytopathic strains of hepatitis A and the murine coronavirus mouse hepatitis virus have been shown to induce rRNA degradation independent of RNase L and of other known viral and cellular ribonucleases (2, 18). Several lines of research are currently underway to determine the identity of this causative ribonuclease, its effects on cell viability and apoptosis, and the biological significance of rRNA degradation induced by ICP0-null HSV-1 infection. In conclusion, ICP0-null HSV-1 infection induces cellular rRNA degradation in a variety of cell types that is independent of the classical RNase L pathway. Furthermore, the resultant degradation is independent of the viral ribonuclease vhs, and ICP0 prevents this cellular response to infection in a manner independent of its E3 ubiquitin ligase activity. Although the specific mechanism of this rRNA degradation remains unknown, these studies indicate the existence of another ICP0-mediated viral countermeasure to the antiviral response against HSV-1 infection, and provide evidence for the existence of a previously unidentified ribonuclease that is part of the host antiviral response to viral infection.

## ACKNOWLEDGEMENTS

We thank R. Silverman, T. Taniguchi, R. Everett, P. Schaffer, S. Read, S. Rice, S. Weller, S. Silverstein and D. Johnson for viral mutants and cell lines and D. Cummings and C. Whitty for technical assistance. This work was sponsored by the Canadian Institutes of Health Research and the U.S. Army Medical Research & Materiel Command. KLM holds an Rx&D Health Sciences Career Award.

# REFERENCES

1. **Aubert, M., and J. A. Blaho.** 1999. The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. *J Virol* **73**:2803-13.
2. **Banerjee, S., S. An, A. Zhou, R. H. Silverman, and S. Makino.** 2000. RNase L-independent specific 28S rRNA cleavage in murine coronavirus-infected cells. *Journal of Virology* **74**:8793-8802.
3. **Boutell, C., S. Sadis, and R. D. Everett.** 2002. Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. *J Virol* **76**:841-50.
4. **Brown, S. M., D. A. Ritchie, and J. H. Subak-Sharpe.** 1973. Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. *J Gen Virol* **18**:329-46.
5. **Cai, W., T. L. Astor, L. M. Lipak, C. Cho, D. M. Coen, and P. A. Schaffer.** 1993. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. *J. Virol.* **67**:7501-7512.
6. **Cai, W., and P. A. Schaffer.** 1989. Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. *J. Virol.* **63**:4570-4589.
7. **Castelli, J., K. A. Wood, and R. J. Youle.** 1998. The 2-5A system in viral infection and apoptosis. *Biomed Pharmacother* **52**:386-90.

- 1 8. **Cayley, P. J., J. A. Davies, K. G. McCullagh, and I. M. Kerr.** 1984. Activation of the  
2 ppp(A2'p)nA system in interferon-treated, herpes simplex virus-infected cells and  
3 evidence for novel inhibitors of the ppp(A2'p)nA-dependent RNase. *Eur J Biochem*  
4 **143:165-174.**
- 5 9. **Chelbi-Alix, M. K., and H. deThe.** 1999. Herpes virus induced proteasome-dependent  
6 degradation of the nuclear bodies-associated PML and Sp100 proteins. *Oncogene*  
7 **18:935-941.**
- 8 10. **DeLuca, N. A., A. M. McCarthy, and P. A. Schaffer.** 1985. Isolation and  
9 characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding  
10 immediate-early regulatory protein ICP4. *Journal of Virology* **56:558-570.**
- 11 11. **Desloges, N., M. Rahaus, and M. H. Wolff.** 2004. Varicella-zoster virus does not  
12 significantly induce the cell defence mechanism mediated by the 2-5A/RNase L pathway  
13 during its replication cycle. *Med Microbiol Immunol (Berl).*
- 14 12. **Eidson, K. M., W. E. Hobbs, B. J. Manning, P. Carlson, and N. A. DeLuca.** 2002.  
15 Expression of Herpes Simplex Virus ICP0 Inhibits the Induction of Interferon-Stimulated  
16 Genes by Viral Infection. *J Virol* **76:2180-91.**
- 17 13. **Everett, R. D.** 1989. Construction and characterization of herpes simplex virus type 1  
18 mutants with defined lesions in immediate early gene 1. *J Gen Virol* **70 ( Pt 5):1185-202.**
- 19 14. **Everett, R. D.** 2000. ICP0, a regulator of herpes simplex virus during lytic and latent  
20 infection. *Bioessays* **22:761-70.**
- 21 15. **Everett, R. D., and G. G. Maul.** 1994. HSV-1 IE protein Vmw110 causes redistribution  
22 of PML. *EMBO J.* **13:5062-5069.**

- 1    16.    **Feng, P., D. N. Everly, Jr., and G. S. Read.** 2001. mRNA decay during herpesvirus  
2           infections: interaction between a putative viral nuclease and a cellular translation factor. *J*  
3           *Virol* **75**:10272-80.
- 4    17.    **Goldstein, D. J., and S. K. Weller.** 1988. Factor(s) present in herpes simplex virus type  
5           1-infected cells can compensate for the loss of the large subunit of the viral  
6           ribonucleotide reductase: characterization of an ICP6 deletion mutant. *Virology* **166**:41-  
7           51.
- 8    18.    **Goswami, B. B., M. Kulka, D. Ngo, and T. A. Cebula.** 2004. Apoptosis induced by a  
9           cytopathic hepatitis A virus is dependent on caspase activation following ribosomal RNA  
10          degradation but occurs in the absence of 2'-5' oligoadenylate synthetase. *Antiviral Res*  
11          **63**:153-66.
- 12   19.    **Houge, G., B. Robaye, T. S. Eikhom, J. Golstein, G. Mellgren, B. T. Gjertsen, M.**  
13          **Lanotte, and S. O. Doskeland.** 1995. Fine mapping of 28S rRNA sites specifically  
14          cleaved in cells undergoing apoptosis. *Mol Cell Biol* **15**:2051-62.
- 15   20.    **Kim, T., T. Y. Kim, Y. H. Song, I. M. Min, J. Yim, and T. K. Kim.** 1999. Activation  
16          of interferon regulatory factor 3 in response to DNA-damaging agents. *J Biol Chem*  
17          **274**:30686-9.
- 18   21.    **Krause, D., and R. H. Silverman.** 1993. Tissue-related and species-specific differences  
19          in the 2-5A oligomer size requirement for activation of 2-5A-dependent RNase. *J*  
20          *Interferon Res* **13**:13-6.
- 21   22.    **Krikorian, C. R., and G. S. Read.** 1991. In vitro mRNA degradation system to study the  
22          virion host shutoff function of herpes simplex virus. *Journal of Virology* **65**::112-122.



- 1 23. **Leaman, D. W., A. Salvekar, R. Patel, G. C. Sen, and G. R. Stark.** 1998. A mutant  
2 cell line defective in response to double-stranded RNA and in regulating basal expression  
3 of interferon-stimulated genes. *Proc Natl Acad Sci U S A* **95**:9442-7.
- 4 24. **Leib, D. A., M. A. Machalek, B. R. Williams, R. H. Silverman, and H. W. Virgin.**  
5 2000. Specific phenotypic restoration of an attenuated virus by knockout of a host  
6 resistance gene. *Proc Natl Acad Sci U S A* **97**:6097-101.
- 7 25. **Lin, R., R. S. Noyce, S. E. Collins, R. D. Everett, and K. L. Mossman.** 2004. The  
8 Herpes Simplex Virus ICP0 RING Finger Domain Inhibits IRF3- and IRF7-Mediated  
9 Activation of Interferon-Stimulated Genes. *J. Virol.* **78**:1675-1684.
- 10 26. **Long, M. C., V. Leong, P. A. Schaffer, C. A. Spencer, and S. A. Rice.** 1999. ICP22  
11 and the UL13 protein kinase are both required for herpes simplex virus-induced  
12 modification of the large subunit of RNA polymerase II. *J. Virol.* **73**:5593-5604.
- 13 27. **Martinand, C., C. Montavon, T. Salehzada, M. Silhol, B. Lebleu, and C. Bisbal.**  
14 1999. RNase L inhibitor is induced during human immunodeficiency virus type 1  
15 infection and down regulates the 2-5A/RNase L pathway in human T cells. *J Virol*  
16 **73**:290-6.
- 17 28. **McCarthy, A. M., L. McMahan, and P. A. Schaffer.** 1989. Herpes simplex virus type 1  
18 ICP27 deletion mutant exhibits altered patterns of transcription and are DNA deficient. *J.*  
19 *Virol.* **63**:18-27.
- 20 29. **Melroe, G. T., N. A. DeLuca, and D. M. Knipe.** 2004. Herpes simplex virus 1 has  
21 multiple mechanisms for blocking virus-induced interferon production. *J Virol* **78**:8411-  
22 20.

- 1 30. **Mossman, K. L., and A. A. Ashkar.** 2005. Herpesviruses and the Innate Immune  
2 Response. *Viral immunology* **18**:267-281.
- 3 31. **Mossman, K. L., P. F. Macgregor, J. J. Rozmus, A. B. Goryachev, A. M. Edwards,**  
4 **and J. R. Smiley.** 2001. Herpes simplex virus triggers and then disarms a host antiviral  
5 response. *Journal of Virology* **75**:750-8.
- 6 32. **Mossman, K. L., H. A. Saffran, and J. R. Smiley.** 2000. Herpes simplex virus ICP0  
7 mutants are hypersensitive to interferon. *Journal of Virology* **74**:2052-6.
- 8 33. **Mossman, K. L., and J. R. Smiley.** 2002. Herpes Simplex Virus ICP0 and ICP34.5  
9 Counteract Distinct Interferon-Induced Barriers to Virus Replication. *J. Virol.* **76**:1995-  
10 1998.
- 11 34. **Muller, S., and A. Dejean.** 1999. Viral immediate-early proteins abrogate the  
12 modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body  
13 disruption. *J. Virol.* **73**:5137-5143.
- 14 35. **Nilsen, T. W., D. L. Wood, and C. Baglioni.** 1981. 2',5'-Oligo(A)-activated  
15 endoribonuclease. Tissue distribution and characterization with a binding assay. *J Biol*  
16 *Chem* **256**:10751-4.
- 17 36. **Player, M. R., and P. F. Torrence.** 1998. The 2-5A system: modulation of viral and  
18 cellular processes through acceleration of RNA degradation. *Pharmacol Ther* **78**:55-113.
- 19 37. **Read, G. S., B. M. Bradley, and K. Knight.** 1993. Isolation of a herpes simplex virus  
20 type 1 mutant with a deletion in the virion host shutoff gene and identification of multiple  
21 forms of the vhs (UL41) polypeptides. *J. Virol.* **67**:7149-7160.
-

- 1    38.    **Sacks, W. R., and P. A. Schaffer.** 1987. Deletion mutants in the gene encoding the  
2        herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell  
3        culture. *J. Virol.* **61**:829-839.
- 4    39.    **Samali, A., B. Gilje, S. O. Doskeland, T. G. Cotter, and G. Houge.** 1997. The ability  
5        to cleave 28S ribosomal RNA during apoptosis is a cell-type dependent trait unrelated to  
6        DNA fragmentation. *Cell Death Differ* **4**:289-293.
- 7    40.    **Samuel, C. E.** 2001. Antiviral actions of interferons. *Clin. Microbiol. Rev.* **14**:778-809.
- 8    41.    **Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakay, M.**  
9        **Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi.** 2000. Distinct and essential roles  
10       of transcription factors IRF-3 and IRF-7 in response to viruses for IFN- $\alpha/\beta$  gene  
11       induction. *Immunity* **13**:539-548.
- 12   42.    **Sen, G. C.** 2001. Viruses and interferon. *Annual Review of Microbiology* **55**:255-281.
- 13   43.    **Sen, G. C., and R. M. Ransohoff.** 1993. Interferon-induced antiviral actions and their  
14       regulation. *Advances in Virus Research* **42**:57-102.
- 15   44.    **Silverman, R. H., and N. M. Cirino.** 1997. RNA decay by the interferon-regulated 2-5A  
16       system as a host defense against viruses, p. 295-309. *In* J. B. Hartford and D. R. Morris  
17       (ed.), *mRNA Metabolism and Post-transcriptional Gene Regulation*. Wiley-Liss Inc.,  
18       New York.
- 19   45.    **Smiley, J. R.** 2004. Herpes Simplex Virus Virion Host Shutoff Protein: Immune Evasion  
20       Mediated by a Viral RNase? *J. Virol.* **78**:1063-1068.
- 21   46.    **Smith, K. O.** 1964. Relationship between the Envelope and the Infectivity of Herpes  
22       Simplex Virus. *Proc Soc Exp Biol Med* **115**:814-6.

- 1 47. **Smith, T. J., R. H. Silverman, and D. A. Leib.** 2003. RNase L activity does not  
2 contribute to host RNA degradation induced by herpes simplex virus infection. *J Gen*  
3 *Virol* **84**:925-8.
- 4 48. **Stow, N. D., and E. C. Stow.** 1986. Isolation and characterization of a herpes simplex  
5 virus type 1 mutant containing a deletion within the gene encoding the immediate-early  
6 polypeptide Vmw110. *J. Gen. Virol.* **67**:2571-2585.
- 7 49. **Tnani, M., and B. A. Bayard.** 1998. Lack of 2',5'-oligoadenylate-dependent RNase  
8 expression in the human hepatoma line HepG2. *Biochim Biophys Acta* **1402**:139-150.
- 9 50. **Umene, K.** 1986. Conversion of a fraction of the unique sequences to part of the inverted  
10 repeats in the S component of the herpes simplex virus type 1 genome. *J. Gen. Virol.*  
11 **67**:1035-1048.
- 12 51. **Uno, T., K. Hirabayashi, M. Murai, J. Yano, and K. Ozato.** 2005. The role of IFN  
13 regulatory factor-3 in the cytotoxic activity of NS-9, a polyinosinic-polycytidylic  
14 acid/cationic liposome complex, against tumor cells. *Mol Cancer Ther* **4**:799-805.
- 15 52. **Williams, B. R.** 1999. PKR: a sentinel kinase for cellular stress. *Oncogene* **18**:6112-  
16 6120.
- 17 53. **Xiang, Y., R. C. Condit, S. Vijaysri, B. Jacobs, B. R. Williams, and R. H. Silverman.**  
18 2002. Blockade of interferon induction and action by the E3L double-stranded RNA  
19 binding proteins of vaccinia virus. *J Virol* **76**:5251-9.
- 20 54. **Yokota, S., N. Yokosawa, T. Kubota, T. Suzutani, I. Yoshida, S. Miura, K. Jimbow,**  
21 **and N. Fujii.** 2001. Herpes simplex virus type 1 suppresses the interferon signaling  
22 pathway by inhibiting phosphorylation of STATs and janus kinases during an early  
23 infection stage. *Virology* **286**:119-124.

- 1 55. **Yokota, S.-i., N. Yokosawa, T. Okabayashi, T. Suzutani, S. Miura, K. Jimbow, and**  
2 **N. Fujii.** 2004. Induction of Suppressor of Cytokine Signaling-3 by Herpes Simplex  
3 Virus Type 1 Contributes to Inhibition of the Interferon Signaling Pathway. *J. Virol.*  
4 **78:6282-6286.**
- 5 56. **Zachos, G., M. Koffa, C. M. Preston, J. B. Clements, and J. Conner.** 2001. Herpes  
6 Simplex Virus Type 1 Blocks the Apoptotic Host Cell Defense Mechanisms That Target  
7 Bcl-2 and Manipulates Activation of p38 Mitogen-Activated Protein Kinase To Improve  
8 Viral Replication. *J. Virol.* **75:2710-2728.**
- 9 57. **Zheng, X., R. H. Silverman, A. Zhou, T. Goto, B. S. Kwon, H. E. Kaufman, and J.**  
10 **M. Hill.** 2001. Increased severity of HSV-1 keratitis and mortality in mice lacking the 2-  
11 5A-dependent RNase L gene. *Invest. Ophthalmol. Vis. Sci.* **42:120-126.**
- 12 58. **Zhou, A., J. Paranjape, T. L. Brown, H. Nie, S. Naik, B. Dong, A. Chang, B. Trapp,**  
13 **R. Fairchild, C. Colmenares, and R. H. Silverman.** 1997. Interferon action and  
14 apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. *Embo*  
15 *J* **16:6355-63.**
- 16 59. **Zhu, X., C. S. H. Young, and S. Silverstein.** 1988. Adenovirus vector expressing  
17 functional herpes simplex virus ICP0. *Journal Virology* **62:4544-4553.**

## FIGURE LEGENDS

**Figure 1.** ICP0 prevents rRNA degradation induced following infection of HEL fibroblasts with HSV-1. RNA gel electrophoresis was performed in fibroblasts treated with Lipofectamine (LF), polyIC or LF+polyIC, or infected with wild-type and mutant HSV-1 viruses of strain KOS (A, B and D) or 17 (C).

**Figure 2.** The extent of rRNA degradation observed following ICP0-null HSV-1 infection is cell type specific. RNA gel analysis was performed on U20S (A) and HepG2 (B) cells transfected with polyIC or infected with the indicated HSVs (strain KOS).

**Figure 3.** The rRNA degradation observed following ICP0-null HSV-1 infection is independent of RNase L. RNA gel analysis of wt MEFs (A) or RNase L<sup>-/-</sup> MEFs (B) transfected with polyIC or infected with wt HSV-1 or ICP0-null HSV-1 (strain KOS).





**Figure 4.** The rRNA degradation observed following ICP0-null HSV-1 infection is independent of the viral ribonuclease vhs. RNA gel analysis of HEL fibroblasts infected with the indicated ICP0-null, vhs-null, or ICP0/vhs-null HSV-1 mutant viruses (strain KOS).

**Figure 5.** ICP0 overexpression does not prevent RNase L-specific rRNA degradation. Vero cells were infected with control adenovirus (AdE1E3) or adenovirus encoding ICP0 (AdMLP0), and subsequently challenged with polyIC transfection (10ng), or HSV-1 infection.


**Figure 6.** The rRNA degradation observed following ICP0-null HSV-1 infection is independent of IRF3. RNA gel analysis was performed on wt MEFs (A) or IRF3<sup>-/-</sup> MEFs (B) transfected with polyIC or infected with the indicated wt and ICP0-null mutant HSVs (strain KOS).


**Table 1.** Properties of HSV-1 viruses used in this study.


Virus	Strain	Mutation	Reference
KOS	KOS	Wild type	(46)
7134	KOS	ICP0-null	(6)
dlX3.1	KOS	ICP0-null	(38)
n212	KOS	ICP0-null	(5)
$\Delta$ sma	KOS	vhs-null	(37)
7134 $\Delta$ sma	KOS	ICP0/vhs-null	(25)
17syn <sup>+</sup>	17	Wild-type	(4)
dl1403	17	ICP0-null	(48)
FXE	17	RING finger deletion	(13)
d22lacZ	KOS	ICP22-null	(26)
N38	KOS	ICP47-null	(50)
$\Delta$ ICP6	KOS	ICP6-null	(17)
d120	KOS	ICP4-null	(10)
5dl1.2	KOS	ICP27-null	(28)















wt MEFs

A



IRF3<sup>-/-</sup> MEFs

B

